Skip to content
DataLookout
Menu

NCT06664983

TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma

StatusUnknown
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Active, Not Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

progression-free survival
Timeframe: from the enrollment to disease progression or death from any cause, assessed up to 12 months

Arms and interventions

TPC chemotherapyActive comparator

NAB-paclitaxel; cisplatin or lobaplatin and capecitabine

Cadonilimab with TPC chemotherapyExperimental

cadonilimab plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin ; and capecitabine

Drugs: TPC chemotherapy, cadonilimab combined TPC chemotherapy

Sites

1 site in 1 country

  • SunYat-senUGuangzhou, Guangdong, China